What did @personalmd actually say?
Honestly, the transcript here is garbled beyond usability. The caption does the heavy lifting: @personalmd claims "Ozempic/Wegovy/Semaglutide are all the same product" and walks viewers through drawing up and injecting 0.25 mg from both a brand-name autoinjector and a compounded vial. That equivalency claim is the one worth examining, because it is not as straightforward as the caption makes it sound.
The video reached nearly 200,000 views, which means a lot of people may be walking away thinking a compounded syringe and a brand-name pen are interchangeable in every meaningful way. They are not, and the distinction matters clinically and legally.
Does the science back up the "same product" claim?
Partially, but the framing is sloppy enough to cause real harm. Semaglutide is the active molecule in both Ozempic and Wegovy. That part is accurate. But "same product" implies identical formulation, manufacturing standards, inactive ingredients, sterility assurance, and regulatory oversight. None of those are guaranteed with compounded versions.
The FDA has been explicit: compounded semaglutide is not FDA-approved and has not undergone the same pre-market review as Ozempic or Wegovy (FDA Drug Shortages, 2024). A 2023 analysis in JAMA (Chua et al., 2023, JAMA) flagged that compounded GLP-1 products sourced from unregulated suppliers may contain semaglutide sodium salt rather than the base form used in approved drugs, which has different pharmacokinetics. "Same molecule" does not mean "same product."
What did they get wrong, and what did they get right?
Wrong: Calling all three "the same product" without qualification is misleading. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management. They use the same molecule at different approved doses and with different labeling, indications, and titration schedules. Treating them as interchangeable ignores that regulatory distinction entirely.
Also wrong by omission: compounded semaglutide entered a legal gray zone when the FDA removed semaglutide from its shortage list in 2024. Compounding pharmacies may no longer legally produce copies of approved semaglutide formulations under federal law, a detail that affects millions of patients and is nowhere in the caption.
What they got right: The 0.25 mg starting dose shown aligns with the standard titration initiation for semaglutide in clinical practice. And showing injection technique is genuinely useful, subcutaneous injection errors are common and contribute to inconsistent absorption (Praet et al., 2019, Diabetes Obesity and Metabolism).
What should you actually know?
If you are currently using compounded semaglutide, talk to a licensed prescriber before assuming it is equivalent to the brand-name version you may have been told it mirrors. The active molecule may be the same, but potency, sterility, and excipient profiles vary by compounding pharmacy and are not independently verified the way FDA-approved drugs are.
A few things worth knowing:
- Ozempic and Wegovy have different FDA-approved indications. Using one off-label for the other's purpose is a prescriber decision, not a patient one.
- Compounded semaglutide may still be available through 503B outsourcing facilities under specific conditions, but the legal landscape changed materially in 2024.
- Injection site, needle angle, and rotation all affect how consistently semaglutide is absorbed. Technique matters regardless of which formulation you use.
- If a compounded product looks, tastes, or smells different from what you expect, contact the dispensing pharmacy and your prescriber. Contamination and mislabeling have been reported (FDA MedWatch, 2024).
The bottom line
The caption's core claim, that all three are "the same product," is the kind of shorthand that makes sense in a casual conversation and causes real problems when 195,000 people take it at face value. Semaglutide is the shared molecule. The products are not the same. That distinction is not a technicality, it affects safety, legality, and what your insurance will or will not cover. Give credit for showing injection technique. Push back hard on the equivalency framing.